Pranlukast

General information

Pranlukast is a leukotriene receptor antagonist. It was developed primarily for the Japanese market and there is little international experience of it. To date, adverse events have occurred in under 1% of patients and gastrointestinal effects were the most common, accounting for 4.7% of reported adverse events [ ].